A comparative study of four serological tumor markers for the detection of breast cancer

Biomedical Sciences Instrumentation

Volumn 39, Issue , 2003, Pages 408-414

  Clinton, Shawn R ^a   Beason, Kevin L ^a   Bryant, Sabrina ^a   Johnson, James T ^a   Jackson, Margaret ^a   Wilson, Cynthia ^a   Holifield, Kay ^a   Vincent, Charlton ^a   Hall, Margot ^a  

^a NONE

Author keywords

AFP; Biomarkers; Breast Cancer; Carcinoembryonic Antigen; Tumor Markers

Indexed keywords

ANTIGENS; DISEASES; HEALTH RISKS; PATIENT TREATMENT; TUMORS;

TUMOR MARKERS;

BIOMEDICAL ENGINEERING;

ALPHA FETOPROTEIN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; SERODIAGNOSIS; SERUM;

EID: 0037261495     PISSN: 00678856     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Abelev, G.I., S.D. Perova, and N.I. Khramkova. 1963. Production ofembryonal alpha globulins by transplantable mouse hepatomas. Transplantation 1:174-180.
2. Beveridge, R.A., D.W. Chan, D. Bruzek, D. Damron, K.R. Bray, P.K. Gaur, D.S. Ettinger, R.C. Rock, M.S. Shurbaji, and F.P. Kuhajda. 1988. A new biomarker in monitoring breast cancer: CA549. J of Clin Oncol 6 (12):1815-1821.
3. Bray, K.R., J.E. Koda, and P.K. Gaur. 1987. Serum levels and biochemical characteristics of cancer-associated antigen CA 549, a circulating breast cancer marker. Cancer Res 47:5853-5860.
4. th Edition W.B.Saunders Co., Philadelphia, PA.
5. Cancer Facts and Figures 2000: Graphical Data. Internet, 2000
6. Chan, D.W., M. Kelsten, R. Rock, and D. Bruzek. 1986. Evaluation of a monoclonal immunoenzymometric assay for alpha-fetoprotein. Clin Chem 32:1318-1322.
7. Clarke, C.A., T.P. Whitehead, and A.G.W. Whitfield. 1982. Carcinoembryonic antigen and smoking. J Royal College of Phys. London 16 (2):112-113.
8. Cooper, M.J., C.R. Mackie, D.B. Skinner, and A.R. Moossa. 1979. A reappraisal of the value of carcinoembryonic antigen in the management ofpatients with various neoplasms. Br J Surg 66:120-123.
9. Frenette, P.S., M.P. Thirlwell, M. Trudeau, D.M. Thomson, L. Joseph, J.S. Shuster. 1994. The diagnostic value of CA 27.29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen, and CA 19-9 in breast cancer and gastrointestinal malignancies. Tumour Biology 15 (5):247-254.
10. Gion, M., and R. Minone. 2001. CA 27.29: a valuable marker for breast cancer management; a confirmatory multicentric study on 603 cases. Eur J Cancer 37 (3):355-63.
11. Hilkens, J., F. Buijs, and J. Hilgers. 1984. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumor. International J. of Cancer 34:197-206.
12. th ed. Springer-Verlag, New York, NY. 389 pp.
13. Hubbard, E. 1990. Tumor markers. Diagnostic and Clinical Testing 28:13-26.
14. rd ed. Oxford University Press, Oxford, England.
15. Knight, G.J., G.E. Palomaki, and J.E. Haddow. 1988. Use of maternal serum alpha-fetoprotein measurements to screen for Down's syndrome. Clin Obstet Gynecol 31:306-327.
16. Kufe, D., G. Inghirami, and M. Abe. 1984. Differential reactivity ofa monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3:223-232.
17. Lauro, S., L. Trasatti, and F. Bordin. 1999. Comparison ofCEA, MCA, CA 15-3 and CA 27.29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res. 19(4C):3511-3515.
18. Milunsky, A. 1987. The prenatal diagnosis of neural tube and other congenital defects. Pages 300-306 in A. Milunsky, ed. Genetic disorders in the fetus: diagnosis, prevention, and treatment. Plenum Press, New York, NY.
19. Pannall, P., and D. Kotasek. 1997. Cancer and clinical biochemistry, ACB Venture Publications, London. 136 pp.
20. Reynoso, G., T.M. Chu, D. Holyoke, E. Cohen, T. Nemoto, and J.J, Wang. 1972. Carcinoembryonic antigen in patients with different cancers. JAMA 220 (3):361-365.
21. Roulston, J.E., and R.C.F. Leonard. 1993. Applications to cancer. Pages 37-51 in J.E. Roulston and R.C.F. Leonard, eds. Serological tumour markers. Churchill Livingstone, New York, NY.
22. Safi, F., I. Kohler, and E. Rottinger. 1991. The value of the tumor marker CA 15-3 in diagnosis and monitoring breast cancer: a comparative study with carcinoembryonic antigen. Cancer 68:574-580.
23. Wu, J., and R. Nakamura. 1997. Human circulating tumor markers. American Society of Clinical Pathologists, Chicago, IL. 263